HOLX shares reached their highest level since May 2011 yesterday, peaking at $23.22 apiece before closing at $22.36, up 7.0% on the day. Shares were trading at $22.39 as of about 12:50 p.m. today.
The Norwegian study, published in the journal Radiology, reviewed the results of 12,631 mammograms and found a 27% increase in detection rates for mammograms using 3D tomosynthesis technology. False-positive rates fell 15% and 25 additional invasive cancers were detected using the 3D technology, for a 40% boost.
"The use of mammography plus tomosynthesis in a screening environment resulted in a significantly higher cancer detection rate and enabled the detection of more invasive cancers," the study’s authors concluded.
"The Oslo trial is the first large-scale prospective study to show the additional cancers found with 3D mammography in combination with 2D mammography were invasive cancers – the very type of cancers we want to detect and treat early. 3D mammography is the best breast screening technology to date in that it finds significantly more invasive cancers while also reducing false positives," Hologic president & CEO Rob Cascella said in prepared remarks.
Analogic to drop $83 million on Ultrasonix
Analogic (NSDQ:ALOG) agreed to pay $83 million for Canadian ultrasound device maker Ultrasonix Medical Corp., saying it expects the deal to boost earnings per share as soon as 2014.
Steris buys out VTS Medical Systems JV partner
Steris (NYSE:STE) said it bought out the remaining interest in its surgical suite monitor joint venture for about $19 million in cash. VTS Medical will be integrated into Steris’s surgical solutions business.
Spectranetics acquires Upstream’s needle & catheter line
Spectranetics (NSDQ:SPNC) said it struck a deal with Upstream Peripheral Technologies and ARAN Research Development & Prototypes to buy the Upstream needle holder, the Upstream support catheter and the Upstream GR guiding balloon catheter for $5.5 million plus $2.5 million in earn-outs and ⅓ of revenues from the product lines in 2014, 2015, and 2016.
Natus buys Astro-Med’s Grass Technologies group
Natus Medical (NSDQ:BABY) said it agreed to pay $18.6 million for Astro-Med’s Grass Technologies line of neurodiagnostic and monitoring devices.
- Analogic (NSDQ:ALOG): Benchmark Company reiterates "buy" rating, $87 price target.
- Boston Scientific (NYSE:BSX): Deutsche Bank maintains “hold” rating, raises price target to $6.70.
- C.R. Bard (NYSE:BCR): Morgan Stanley downgrades to “underweight” rating, $91 price target.
- Hologic (NSDQ:HOLX): Leerink Swann maintains "outperform" rating, $25 price target.
- Medtronic (NYSE:MDT): Wunderlich reiterates "buy" rating, $46 price target.
- NuVasive Inc. (NSDQ:NUVA): Leerink Swann maintains "market perform" rating, $16 price target.
- St. Jude Medical (NYSE:STJ): Leerink Swann maintains “outperform” rating, ~$50 price target.
- Stryker (NYSE:SYK): Leerink Swann maintains "outperform" rating, ~$61 price target.
- Syneron Medical Ltd. (NSDQ:ELOS): Zacks upgrades from “neutral” to “outperform” rating, $9.70 price target.